CL2015003023A1 - Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. - Google Patents

Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.

Info

Publication number
CL2015003023A1
CL2015003023A1 CL2015003023A CL2015003023A CL2015003023A1 CL 2015003023 A1 CL2015003023 A1 CL 2015003023A1 CL 2015003023 A CL2015003023 A CL 2015003023A CL 2015003023 A CL2015003023 A CL 2015003023A CL 2015003023 A1 CL2015003023 A1 CL 2015003023A1
Authority
CL
Chile
Prior art keywords
bimatoprost
sustained release
prostamides
prostaglandins
analogs
Prior art date
Application number
CL2015003023A
Other languages
English (en)
Inventor
Scott M Whitcup
David F Woodward
Patrick M Hughes
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CL2015003023A1 publication Critical patent/CL2015003023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)

Abstract

METODO DE REDUCCION DE GRASA QUE COMPRENDE INYECTAR UNA FORMULACION DE LIBERACION SOSTENIDA EN UN DEPOSITO DE GRASA; Y COMPOSICION DE LIBERACION SOSTENIDA QUE COMPRENDE BIMATOPROST, ANALOGOS DO BIMATOPROST, PROSTAMIDAS, PROSTAGLANDINAS, ANALOGOS DE PROSTAGLANDINA, LATANOPROST Y TRAVOPROST Y DERIVADOS DE PROSTAGLANDINA.
CL2015003023A 2013-04-12 2015-10-09 Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas. CL2015003023A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361811682P 2013-04-12 2013-04-12

Publications (1)

Publication Number Publication Date
CL2015003023A1 true CL2015003023A1 (es) 2016-06-10

Family

ID=51686960

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003023A CL2015003023A1 (es) 2013-04-12 2015-10-09 Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.

Country Status (19)

Country Link
US (2) US20140308354A1 (es)
EP (2) EP2983663B1 (es)
JP (1) JP2016520561A (es)
KR (1) KR20150141972A (es)
CN (2) CN105101962A (es)
AU (2) AU2014250937A1 (es)
BR (1) BR112015025915A8 (es)
CA (1) CA2908731A1 (es)
CL (1) CL2015003023A1 (es)
DK (1) DK2983663T3 (es)
ES (1) ES2785382T3 (es)
HK (1) HK1221406A1 (es)
IL (1) IL242006B (es)
MX (1) MX2015014320A (es)
MY (1) MY187802A (es)
RU (1) RU2015143859A (es)
SG (2) SG10202109919PA (es)
WO (1) WO2014169075A1 (es)
ZA (1) ZA201507217B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176640A1 (en) * 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
US11452703B2 (en) 2020-05-21 2022-09-27 Peregrine Ophthalmic PTE LTD. Methods and compositions for reducing adipocyte numbers
AU2021313151A1 (en) * 2020-07-21 2023-03-16 Allergan, Inc. Intraocular implant with high loading of a prostamide

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2218424A (en) * 1931-05-07 1940-10-15 Teleregister Corp Transmitter and code translator
US4525359A (en) * 1982-12-10 1985-06-25 Greenway Frank L Iii Treatment for selective weight control
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
CA2221110C (en) * 1995-05-18 2009-08-04 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents for the treatment of ocular hypertension
ES2379652T3 (es) 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
CN100453066C (zh) * 2002-12-04 2009-01-21 参天制药株式会社 利用结膜下储存库的药物释放系统
AU2004308971A1 (en) * 2003-12-22 2005-07-14 Aventis Pharmaceuticals Inc. Injectable phosphatidylcholine preparations
US20080038316A1 (en) 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
WO2007111806A2 (en) 2006-03-23 2007-10-04 Massachusetts Eye And Ear Infirmary Cyclopentane heptanoic acid compounds for reducing body fat
AU2007313077B2 (en) * 2006-10-17 2011-06-02 Neothetics, Inc. Methods, compositions, and formulations for the treatment of thyroid eye disease
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US9095506B2 (en) * 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2011109384A2 (en) * 2010-03-02 2011-09-09 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure
US20120022137A1 (en) 2010-07-21 2012-01-26 Rivers Hongwen M METHOD OF CONTROLLING INITIAL DRUG RELEASE OF siRNA FROM SUSTAINED-RELEASE IMPLANTS
CN105073153B (zh) * 2013-03-15 2018-10-30 阿勒根公司 含有前列腺胺的眼内植入物
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Also Published As

Publication number Publication date
EP3656375A1 (en) 2020-05-27
ES2785382T3 (es) 2020-10-06
SG10201701938PA (en) 2017-04-27
WO2014169075A1 (en) 2014-10-16
JP2016520561A (ja) 2016-07-14
DK2983663T3 (da) 2020-04-20
RU2015143859A (ru) 2017-05-16
AU2019203214B2 (en) 2020-10-29
AU2019203214A1 (en) 2019-05-30
RU2015143859A3 (es) 2018-03-05
BR112015025915A2 (pt) 2017-07-25
CN110840899A (zh) 2020-02-28
EP2983663B1 (en) 2020-01-22
US20160339039A1 (en) 2016-11-24
ZA201507217B (en) 2017-09-27
BR112015025915A8 (pt) 2020-01-14
KR20150141972A (ko) 2015-12-21
EP2983663A1 (en) 2016-02-17
MY187802A (en) 2021-10-26
CN105101962A (zh) 2015-11-25
NZ712804A (en) 2021-02-26
SG10202109919PA (en) 2021-10-28
CA2908731A1 (en) 2014-10-16
US10682361B2 (en) 2020-06-16
US20140308354A1 (en) 2014-10-16
IL242006B (en) 2020-04-30
HK1221406A1 (zh) 2017-06-02
AU2014250937A1 (en) 2015-10-22
MX2015014320A (es) 2015-12-08

Similar Documents

Publication Publication Date Title
CL2015003270A1 (es) Composiciones y métodos para el suministro tópico de prostaglandinas a la grasa subcutanea.
CR20160212A (es) Composiciones y métodos para modular los receptores x farnesoides
CR20130639A (es) Sistemas y métodos basados en tomografía de coherencia óptica y presión
ECSP18014922A (es) Composiciones de insulina de rápida acción
BR112014024903A2 (pt) anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
PE20160506A1 (es) Anticuerpos biespecificos especificos para fap y dr5, anticuerpos especificos para dr5 y metodos de utilizacion
CR20160154A (es) Ácidos grasos octanoico, nonanoico y decanoico con un adulticida piretroide
CL2014000759A1 (es) Composicion para uso en el crecimiento del cerebro y/o desarrollo cognitivo y/o desarrollo psicomotor que comprende al menos un ácido graso poliinsaturado de cadena larga (lc-pufa), al menos un probiótico y una mezcla de oligosacáridos; uso de la composición.
UY34697A (es) Métodos para preparar análogos de nucleótidos
CR20160061A (es) Formulación estable líquida de etelcalcetide (amg 461)
DOP2013000293A (es) Composiciones líquidas de limpieza de sal
BR112015022347A2 (pt) composição para vacinação, método para produzir uma composição para vacinação e uso de composição
UY35776A (es) ?antagonistas de receptor ep3 de prostaglandina?.
CL2016002531A1 (es) Composición de ácidos grasos monoinsaturados de cadena larga y métodos para la producción de la misma
CL2015001559A1 (es) Dispersión solida de un modulador selectivo de los receptores de progesterona
CL2015003023A1 (es) Liberacion sostenida de bimatoprost, analogos de bimatoprost, prostamidas y prostaglandinas para la reduccion de grasas.
CO2017005843A2 (es) Método para reducir las grasas totales y saturadas en rellenos de productos de confitería
BR112013019924A8 (pt) Composições para cuidado oral
CL2015000240A1 (es) Formulación transdérmica que contiene inhibidores de cox
UY35823A (es) Profármacos de antagonista de nmda
DOP2017000264A (es) Metodo para crear un compuesto a base de mercurio, compuesto a base de mercurio, metodos de uso del compuesto a base de mercurio y usos del compuesto a base de mercurio
TWD187972S (zh) 泵桿式制動器
CL2016001062A1 (es) Composiciones y métodos para administración de una enzima a las vías respiratorias de un sujeto
PE20151432A1 (es) Formulaciones de lorazepam de liberacion sostenida
EA201390435A1 (ru) Способ выпрямления волос